Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

Trends in Molecular Medicine

Volumn 21, Issue 1, 2015, Pages 24-33

  Ohaegbulam, Kim C ^a   Assal, Amer ^b   Lazar Molnar, Eszter ^c   Yao, Yu ^d   Zang, Xingxing ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d FUDAN UNIVERSITY   (China)

Author keywords

Human cancer; Immunotherapy; Monoclonal antibody; PD 1; PD L1; PD L2

Indexed keywords

AMP 224; BMS 936559; DURVALUMAB; MONOCLONAL ANTIBODY; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1 MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; HUMAN; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MICROENVIRONMENT; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN STRUCTURE; REVIEW; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; T LYMPHOCYTE;

ANIMALS; ANTIBODIES; ANTIGENS, CD274; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 84925529257     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2014.10.009     Document Type: Review

References (88)

1. Keir M.E., et al. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26:677-704.
2. Ishida Y., et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992, 11:3887-3895.
3. Barber D.L., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
4. Wherry E.J. T cell exhaustion. Nat. Immunol. 2011, 12:492-499.
5. Hofmeyer K.A., et al. The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion. J. Biomed. Biotechnol. 2011, 2011:451694.
6. Francisco L.M., et al. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 2010, 236:219-242.
7. Francisco L.M., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 2009, 206:3015-3029.
8. + cells. J. Exp. Med. 2008, 205:565-574.
9. Thibult M.L., et al. PD-1 is a novel regulator of human B-cell activation. Int. Immunol. 2013, 25:129-137.
10. Nicholas K.J., et al. B cell responses to HIV antigen are a potent correlate of viremia in HIV-1 infection and improve with PD-1 blockade. PLoS ONE 2013, 8:e84185.
11. Dong H., et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 1999, 5:1365-1369.
12. Freeman G.J., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000, 192:1027-1034.
13. Latchman Y., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2001, 2:261-268.
14. Tseng S.Y., et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 2001, 193:839-846.
15. Atefi M., et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin. Cancer Res. 2014, 20:3446-3457.
16. Parsa A.T., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 2007, 13:84-88.
17. Butte M.J., et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007, 27:111-122.
18. Xiao Y., et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J. Exp. Med. 2014, 211:943-959.
19. Zhang X., et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 2004, 20:337-347.
20. Cheng X., et al. Structure and interactions of the human programmed cell death 1 receptor. J. Biol. Chem. 2013, 288:11771-11785.
21. Lin D.Y., et al. The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:3011-3016.
22. Lazar-Molnar E., et al. Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10483-10488.
23. Parry R.V., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 2005, 25:9543-9553.
24. Zang X., Allison J.P. The B7 family and cancer therapy: costimulation and coinhibition. Clin. Cancer Res. 2007, 13:5271-5279.
25. John L.B., et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 2013, 19:5636-5646.
26. Curran M.A., et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:4275-4280.
27. + T-Cell responses through the PD-1-PD-L1 Axis. Cancer Res. 2014, 74:3441-3453.
28. Deng L., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 2014, 124:687-695.
29. Berger R., et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 2008, 14:3044-3051.
30. Hardy B., et al. Activation of human lymphocytes by a monoclonal antibody to B lymphoblastoid cells; molecular mass and distribution of binding protein. Cancer Immunol. Immunother. 1995, 40:376-382.
31. Westin J.R., et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, Phase 2 trial. Lancet Oncol. 2014, 15:69-77.
32. Armand P., et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international Phase II trial. J. Clin. Oncol. 2013, 31:4199-4206.
33. Patnaik A., et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. ASCO Meeting Abstracts 2012, 30:2512.
34. Hamid O., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013, 369:134-144.
35. Daud A.I., et al. Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma (MEL): correlation of tumor PD-L1 expression with outcome [abstract]. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research 2014.
36. Robert C., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a Phase 1 trial. Lancet 2014, 384:1109-1117.
37. Wong R.M., et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int. Immunol. 2007, 19:1223-1234.
38. Hi regulatory T cells. Int. Immunol. 2009, 21:1065-1077.
39. Brahmer J.R., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010, 28:3167-3175.
40. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
41. Brahmer J.R., et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. ASCO Meeting Abstracts 2014, 32:8112.
42. Hodi F.S., et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a Phase I trial. ASCO Meeting Abstracts 2014, 32:9002.
43. Wolchok J.D., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369:122-133.
44. Brahmer J.R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366:2455-2465.
45. Beck A., et al. 6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland. MAbs 2011, 3:111-132.
46. Lutzky J., et al. A Phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors. ASCO Meeting Abstracts 2014, 32:3001.
47. Segal N.H., et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. ASCO Meeting Abstracts 2014, 32:3002.
48. Callahan M.K., et al. A Phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. ASCO Meeting Abstracts 2014, 32:TPS3120.
49. Powles T., et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). ASCO Meeting Abstracts 2014, 32:5011.
50. Herbst R.S., et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. ASCO Meeting Abstracts 2013, 31:3000.
51. Heery C.R., et al. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. ASCO Meeting Abstracts 2014, 32:3064.
52. Mkrtichyan M., et al. B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets. J. Immunol. 2012, 189:2338-2347.
53. Infante J.R., et al. Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor. ASCO Meeting Abstracts 2013, 31:3044.
54. + immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol. Immunother. 2014, 63:395-406.
55. Muenst S., et al. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res. Treat. 2013, 139:667-676.
56. +. Prostate 2009, 69:1694-1703.
57. + T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2012, 97:E934-E943.
58. Ahmadzadeh M., et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114:1537-1544.
59. Chapon M., et al. Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes. J. Invest. Dermatol. 2011, 131:1300-1307.
60. + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:7875-7880.
61. Thompson R.H., et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res. 2007, 13:1757-1761.
62. + T lymphocytes in human non-small cell lung cancer. Cell. Mol. Immunol. 2010, 7:389-395.
63. + T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int. J. Cancer 2011, 128:887-896.
64. Shi S.J., et al. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS ONE 2013, 8:e76012.
65. + T-cell infiltration and survival of patients with cervical carcinoma. Clin. Cancer Res. 2009, 15:6341-6347.
66. Nomi T., et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 2007, 13:2151-2157.
67. Muenst S., et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res. Treat. 2014, 146:15-24.
68. Maine C.J., et al. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol. Immunother. 2014, 63:215-224.
69. + T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:3360-3365.
70. Frigola X., et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin. Cancer Res. 2011, 17:1915-1923.
71. Thompson R.H., et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006, 66:3381-3385.
72. Gao Q., et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin. Cancer Res. 2009, 15:971-979.
73. Azuma K., et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected non-small cell lung cancer. Ann. Oncol. 2014, 25:1935-1940.
74. Hino R., et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010, 116:1757-1766.
75. Massi D., et al. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann. Oncol. 2014, Published online September 15, 2014. http://dx.doi.org/10.1093/annonc/mdu452.
76. Ohigashi Y., et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 2005, 11:2947-2953.
77. Atkins M.B., et al. Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. ASCO Meeting Abstracts 2014, 32:9001.
78. Garon E.B., et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2014, 32:8020.
79. Felip E., et al. Developmental therapeutics. Ann. Oncol. 2012, 23:ix152-ix174.
80. Motzer R.J., et al. Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging Phase II trial. ASCO Meeting Abstracts 2014, 32:5009.
81. Hamanishi J., et al. Efficacy and safety of anti-PD-1 antibody (nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. ASCO Meeting Abstracts 2014, 32:5511.
82. Cho D.C., et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 2013, 31:4505.
83. Hamid O., et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). ASCO Meeting Abstracts 2013, 31:9010.
84. Spigel D.R., et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2013, 31:8008.
85. Rizvi N.A., et al. A Phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). ASCO Meeting Abstracts 2013, 31:8072.
86. Antonia S.J., et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. ASCO Meeting Abstracts 2014, 32:8023.
87. Hammers H.J., et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 2014, 32:4504.
88. Weber J.S., et al. Phase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab. ASCO Meeting Abstracts 2013, 31:9011.